Urogen Pharma

$7.47 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Urogen Pharma

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Stock Analysis

last close $8.04
1-mo return -17.2%
3-mo return -51.2%
avg daily vol. 134.63T
52-week high 28.2
52-week low 7.65
market cap. $190M
forward pe -
annual div. -
roe -148.5%
ltg forecast -
dividend yield -
annual rev. $40M
inst own. 78.1%

Subscribe now for daily local and international financial news